SYRS News and Press, Syros Pharmaceuticals Inc.

2025-04-15 06:41:18 ET ... Read the full article on Seeking Alpha For further details see: Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals

2025-04-06 18:49:24 ET Syros Pharmaceuticals, Inc. (SYRS) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 6.95%. The average open to low on the day of earnings was -6.45%. The average op...

2025-04-06 18:44:22 ET Syros Pharmaceuticals, Inc. (SYRS) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in SYRS stock price following earnings has averaged ±3.45% , with a median of 3.0...

Nu Ride Inc. - Class A (NRDE) is expected to report for quarter end 2024-12-31 Dalrada Financial Corp. (DFCO) is expected to report for quarter end 2024-12-31 HilleVax Inc. (HLVX) is expected to report $-0.38 for Q4 2024 Chewy Inc. Class A (CHWY) is expected to report $0.03 for Q4 202...

2025-02-28 16:23:36 ET More on Syros Pharmaceuticals Seeking Alpha’s Quant Rating on Syros Pharmaceuticals Historical earnings data for Syros Pharmaceuticals Financial information for Syros Pharmaceuticals Read the full article on Seeking Alpha ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market (“Nasdaq”) an...

2025-02-13 18:05:28 ET Summary Company is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. The company is also progressing REC-994 for Cerebral Cavernous Malformation, wi...